NVO

Novo Releases Inaugural Sustainability Statement

Retrieved on: 
Wednesday, November 16, 2022
NVO, TSX, Risk, Beaton Creek, Materiality, Legislation, ERM, SEDAR, News, Environmental resource management, Novo, Statement, Risk management, Audit

VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) is pleased to announce that it has published its inaugural sustainability statement (the Statement) for the 12-month period ended June 30, 2022.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) is pleased to announce that it has published its inaugural sustainability statement (the Statement) for the 12-month period ended June 30, 2022.
  • Novo invites all of its stakeholders to read the Statement and watch the accompanying introductory video from the Novo team ( available here ), in which the Company outlines its approach to sustainability and its foundation built on key pillars that integrate all aspects of Novos operations.
  • In addition to the Companys primary focus, Novo seeks to leverage its internal geological expertise to deliver value-accretive opportunities to its shareholders.
  • If Novo updates any forward-looking statement(s), no inference should be drawn that the Company will make additional updates with respect to those or other forward-looking statements.

Bigfoot Biomedical Announces Insulin Compatibility Expansion to Support Insulin Affordability and Flexibility for People with Diabetes

Retrieved on: 
Monday, November 7, 2022
Biotechnology, Insurance, Pharmaceutical, Health, Diabetes, Medical Devices, Professional Services, Health Insurance, Insulin, Medicare, Biomedicine, Bigfoot Biomedical, FDA, Bigfoot, Population, NYSE, Medicaid, Insulin aspart, CEO, Walmart, Novo Nordisk, CGM, Diabetes, NVO, Technology, Club, Insurance, American Diabetes Association, Pharmaceutical industry, Facebook, Lilly, Insulin lispro

It is a critical part of our mission, said Jeffrey Brewer, CEO of Bigfoot Biomedical.

Key Points: 
  • It is a critical part of our mission, said Jeffrey Brewer, CEO of Bigfoot Biomedical.
  • Our expansion of compatibility to include additional insulin brands will make it easier for Bigfoot to support a broader population of people with insulin-requiring diabetes and will give Bigfoot Unity users greater flexibility to switch between insulin brands when they have a change in insurance.
  • This news marks an important moment in time for Bigfoot as we strive to make insulin diabetes management tools more accessible for people who need them.
  • Bigfoot Biomedical was founded by a team of people with personal connections to Type 1 and Type 2 diabetes.

Pandemic Response Lab Launches Novel Triple-target Monkeypox Tests

Retrieved on: 
Thursday, October 13, 2022
Health, Infectious Diseases, Health Technology, COVID-19, General Health, Pharmaceutical, Biotechnology, Monkeypox virus, Physician, U.S. Department of Defense Strategy for Operating in Cyberspace, CDC, Infection, Virus, Human services, Laboratory, PRL, Severe acute respiratory syndrome coronavirus 2, Patient, Monkeypox, NVO, PCR, Center, World, Industry, National Health Laboratory Service, World Health Organization, Leadership, Office of Inspector General, U.S. Department of Health and Human Services, Korea Disease Control and Prevention Agency, NAA, Genome, DNA, Disease management, COVID-19, Public health, Vaccine

Pandemic Response Lab (PRL), a wholly owned subsidiary of Opentrons Labworks, Inc., today announced two new three-target monkeypox tests , each developed and performed by its New York and Maryland laboratories, respectively.

Key Points: 
  • Pandemic Response Lab (PRL), a wholly owned subsidiary of Opentrons Labworks, Inc., today announced two new three-target monkeypox tests , each developed and performed by its New York and Maryland laboratories, respectively.
  • These skin lesion tests qualitatively detect three different viral genome targets of increasing specificity: non-variola orthopoxvirus, monkeypox virus species and monkeypox virus clade II.
  • Our multi-target monkeypox tests include confirmatory results rather than presumptive positive results and do not need additional confirmatory testing.
  • Pandemic Response Lab, a wholly owned subsidiary of Opentrons Labworks, Inc., launched in 2020 in response to the COVID-19 pandemic to address the pressing need to make rapid, accurate and low-cost testing equitably accessible to all populations.

Nullagine Gold Production Update

Retrieved on: 
Tuesday, October 11, 2022
Adoption, News, Golden eagle, National instrument, Golden Crown, Risk, Government, TSX, Carbon, NVO, Environmental protection, Gold, Company, Silver, Mineral, Board, Rehabilitation, GLOBE, COVID-19, Compliance, Medical device, Uranium, Palladium, Risk management, Beaton Creek, Becher

VANCOUVER, British Columbia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Novo Resources Corp. (“Novo” or the “Company”) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) provides a 2022 third quarter (“Q3 2022”) operational update for the Beatons Creek gold project (“Beatons Creek”) and Golden Eagle processing facility (“Golden Eagle Plant”), located in Nullagine, Western Australia.

Key Points: 
  • Gold production totalled 13,137 ounces and recovery rates of approximately 90.7% were achieved in Q3 2022.
  • Q3 2022 gold sales totalled 12,426 ounces of gold and 1,336 ounces of silver for gross revenue of C$28.0 million (A$31.4 million)3.
  • Throughout Phase One operations at Beatons Creek, Novo has sold its gold in Australian dollars to ABC Refinery of Sydney, Australia and enjoyed strong gold price performance in Australian dollar terms.
  • Failure to achieve the anticipated production costs had a material adverse impact on the Companys cash flow and future profitability.

FORMA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX

Retrieved on: 
Tuesday, September 27, 2022
Class Action Lawsuit, Professional Services, Legal, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., KSF, NVO, Company, Time, Novo Nordisk, NYSE, Sale, LLC, Sales, Forma

and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Forma Therapeutics, Holdings Inc. (NasdaqGM: FMTX) to Novo Nordisk A/S (NYSE: NVO).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Forma Therapeutics, Holdings Inc. (NasdaqGM: FMTX) to Novo Nordisk A/S (NYSE: NVO).
  • Under the terms of the proposed transaction, shareholders of Forma will receive $20 in cash for each share of Forma that they own.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

FORMA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX

Retrieved on: 
Friday, September 2, 2022
Class Action Lawsuit, Professional Services, Legal, NVO, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., LLC, Sale, NYSE, Novo Nordisk, Company, KSF, Time, Sales, Forma

and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Forma Therapeutics, Holdings Inc. (NasdaqGM: FMTX) to Novo Nordisk A/S (NYSE: NVO).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Forma Therapeutics, Holdings Inc. (NasdaqGM: FMTX) to Novo Nordisk A/S (NYSE: NVO).
  • Under the terms of the proposed transaction, shareholders of Forma will receive $20 in cash for each share of Forma that they own.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

DGAP-News: Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst

Retrieved on: 
Thursday, September 1, 2022
Back pain, Advertising, Safety, NYSE, Obesity, Pain, Research, Vertex Inc, NASDAQ, PFE, Mouse, Novo Nordisk, Pain scale, Food, Microdeletion syndrome, Department, Lists of diseases, Food and Drug Administration, Department of Defense Serum Repository, Pfizer, Acceleration, Disability, VRTX, Neck pain, Leadership, KOLS, Company, FDA, NVO, Adult, Diabetes, Low back pain, Patient, Consumer electronics, Pharmaceutical industry, Poultry

In the same year, medical costs for adult obesity in the United States were $260.6 billion.

Key Points: 
  • In the same year, medical costs for adult obesity in the United States were $260.6 billion.
  • Thats why BioRestorative Therapies Inc. (NASDAQ: BRTX) is working to develop treatments for these 2 indications, laser-focusing on obesity and lower back pain.
  • BioRestorative Therapies leadership is excited about the companys ability to continue developing its two major technologies that could potentially provide access to multibillion-dollar markets.
  • BioRestorative plans to unveil major safety data for its new therapies within the first quarter of 2023.

DGAP-News: Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated

Retrieved on: 
Friday, August 19, 2022
FDA, Novo, Type 2 diabetes, Semaglutide, Pharmacy, Risk, Injection, NYSE, Technology, Database, Novo Nordisk, Pain, Express Scripts, Insulin, LLY, Patient, Eli Lilly and Company, NVO, Company, Program, NASDAQ, OTCQB, Cigna, Diabetes, CI, Insurance, Type 2, Advertising, Regulation of tobacco by the U.S. Food and Drug Administration, Food, SNY, Pharmaceutical industry, Medical imaging, Dietary supplement

Americans with diabetes have been relying on insulin injections to manage their illness for decades.

Key Points: 
  • Americans with diabetes have been relying on insulin injections to manage their illness for decades.
  • The U.S. Food and Drug Administration (FDA) recently approved Rybelsus, also known as oral semaglutide, which controls blood sugar in Type 2 diabetes patients.
  • Still, the company claims it is committed to working with health insurance providers and pharmacy benefit managers to increase patient access.
  • This could be a significant milestone towards regulatory clearance and ultimately product commercialization, potentially changing the lives of millions worldwide.

Novo Completes Full Repayment and Retirement of US$40 Million Sprott Lending Credit Facility

Retrieved on: 
Friday, August 12, 2022
Novo, GLOBE, Sale, TSX, Board, Primary Dealer Credit Facility, NVO, Company, Beaton Creek, Line of credit, Bank

VANCOUVER, British Columbia, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) is pleased to advise that it has completed repayment of its senior secured US$40 million credit facility (Credit Facility) with Sprott Resource Lending Corp. (Sprott) subsequent to the completion of the sale of the Companys New Found Gold Corp. investment1.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) is pleased to advise that it has completed repayment of its senior secured US$40 million credit facility (Credit Facility) with Sprott Resource Lending Corp. (Sprott) subsequent to the completion of the sale of the Companys New Found Gold Corp. investment1.
  • The Company is now free of long-term borrowings, with an unaudited consolidated cash balance of C$76.6 million.
  • The Company paid an aggregate amount of US$40,144,029 to Sprott in satisfaction of all amounts outstanding, including all accrued interest, on the Credit Facility.
  • The Company is in the process of discharging all security previously granted to Sprott in connection with the Credit Facility.

Novo Completes Second and Final Tranche of Sale of New Found Gold Shares for C$57.0 Million

Retrieved on: 
Monday, August 8, 2022
Risk, Tranche, GLOBE, Sprot, Mineral, Sale, TSX, Regulation, National instrument, Primary Dealer Credit Facility, Director, Board, EPA, NVO, Company, Transaction, Beaton Creek, Environmental protection, Groundwater, News, Line of credit, US, Risk management, Safety

In the second tranche, Novo sold a total of 6.75 million escrowed New Found shares to a corporation controlled by Eric Sprott (Sprott) at C$8.45 per share for gross proceeds of approximately C$57.0 million (Tranche 2).

Key Points: 
  • In the second tranche, Novo sold a total of 6.75 million escrowed New Found shares to a corporation controlled by Eric Sprott (Sprott) at C$8.45 per share for gross proceeds of approximately C$57.0 million (Tranche 2).
  • Inclusive of the gross proceeds raised from the sale of 8.25 million New Found shares sold to Sprott at C$8.35 per share in the first tranche1, gross proceeds of approximately C$125.9 million have been raised from the Transaction.
  • Novos consolidated unaudited cash position is currently approximately C$126.4 million.
  • In addition to the Companys primary focus, Novo seeks to leverage its internal geological expertise to deliver value-accretive opportunities to its shareholders.